Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects

NCT04638634 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

12

Enrollment

INDUSTRY

Sponsor class

Stopped For business reasons, not a safety issue

Conditions

Coronavirus Disease 2019 (COVID-19)

Interventions

BIOLOGICAL: CSL760

Sponsor

CSL Behring